Clinical trials: Recurrent Calcium Oxalate Kidney Stone Disease
Hyperoxaluria, Nephrolithiasis
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
The purpose of this study is to evaluate the effect of ALLN-177 to reduce urinary oxalate excretion in patients with recurring kidney stones and enteric or idiopathic hyperoxaluria.
- Trial name
- NCT02289755
- Testing
- ALLN-177
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Allena Pharmaceuticals
Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Urinary Oxalate Levels
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
The primary purpose of this study is to evaluate the effect of lumasiran on the percent change in urinary oxalate excretion in patients with recurrent calcium oxalate kidney stone disease.
- Trial name
- NCT05161936
- Testing
- Lumasiran
- Where
- 31 sites in United States, Belgium and 4 more
- Volunteers
- 2 people
- Sponsor
- Alnylam Pharmaceuticals